PD-1 antibody and radiation for advanced adrenal cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adrenal cortical carcinoma that has come back or spread.
- You are 18 years or older.
- Your cancer has gotten worse after at least one prior treatment (like mitotane or chemotherapy).
- You have at least one tumor that can be measured on scans.
- You have not had radiation therapy to the tumor area before.
- You have not taken any other PD-1 or PD-L1 inhibitor drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
This Phase 2 trial studies pembrolizumab (an immune therapy) in people with advanced adrenocortical carcinoma that has progressed despite prior chemotherapy. It aims to shrink tumors or slow growth by helping the immune system recognize the cancer.
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
This trial tests whether giving radiation therapy after surgery for adrenocortical carcinoma (a rare cancer of the adrenal gland) can improve outcomes compared to just watching and waiting. It is for patients who have certain high-risk features that make the cancer more likely to come back.
This trial tests two targeted drugs, anlotinib and benmelstobart, for people with advanced pheochromocytoma or paraganglioma that has spread or come back after treatment. These drugs may help shrink tumors or slow their growth.
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Hear when a new Adrenocortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.